Cytokinetics, Incorporated (CYTK) Financial Statements (2024 and earlier)

Company Profile

Business Address 350 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:829,300623,700501,000267,800198,700285,400
Cash and cash equivalents65,582112,66682,98536,43342,256125,206
Short-term investments716,995358,972381,075189,679156,475143,685
Other undisclosed cash, cash equivalents, and short-term investments46,723152,06236,94041,688(31)16,509
Receivables14751,8194,4205,1632,2311,112
Contract with customer, asset, after allowance for credit loss     4,554
Other undisclosed current assets(34,261)(139,847)(31,199)(39,211)2,189(12,217)
Total current assets:795,186535,672474,221233,752207,674274,295
Noncurrent Assets
Operating lease, right-of-use asset82,73773,138  
Property, plant and equipment80,45373,27113,3464,5303,2043,568
Long-term investments and receivables46,708152,050   16,518
Long-term investments46,708152,050   16,518
Other noncurrent assets9,6917,188  300429
Other undisclosed noncurrent assets   46,23651,532  
Total noncurrent assets:219,589305,64759,58256,0623,50420,515
TOTAL ASSETS:1,014,775841,319533,803289,814211,178294,810
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities69,70755,45727,36520,28319,52122,645
Accounts payable25,61121,0878,0508,1603,7645,253
Accrued liabilities44,09634,37019,31512,12315,75717,392
Debt    4,6162,607 
Deferred revenue and credits9,572
Other liabilities2,0811,5401,0491,12466227
Other undisclosed current liabilities12,82914,8632,785   
Total current liabilities:84,61771,86031,19926,02322,19432,444
Noncurrent Liabilities
Long-term debt and lease obligation63,810159,59646,20947,24739,80631,777
Long-term debt, excluding current maturities63,81047,36746,20945,05239,80631,777
Liabilities, other than long-term debt127,93991,45787,000 77116,097
Deferred revenue and credits15,000
Deferred revenue  87,00087,000 
Other liabilities1,0444,457  7711,097
Operating lease, liability126,895112,229 2,195
Other undisclosed noncurrent liabilities846,309274,543256,012227,481122,473104,650
Total noncurrent liabilities:1,038,058525,596389,221274,728163,050152,524
Total liabilities:1,122,675597,456420,420300,751185,244184,968
Equity
Equity, attributable to parent(107,900)243,863113,383(10,937)25,934109,842
Common stock948470595554
Additional paid in capital1,481,5901,452,2681,105,470853,341768,703755,526
Accumulated other comprehensive income (loss)(3,590)(869)149679500343
Accumulated deficit(1,585,994)(1,207,620)(992,306)(865,016)(743,324)(646,081)
Total equity:(107,900)243,863113,383(10,937)25,934109,842
TOTAL LIABILITIES AND EQUITY:1,014,775841,319533,803289,814211,178294,810

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues94,58870,42855,82826,86831,50113,368
Revenue, net8,799
Gross profit:94,58870,42855,82826,86831,50113,368
Operating expenses(418,790)(256,741)(149,771)(125,735)(120,417)(126,764)
Operating loss:(324,202)(186,313)(93,943)(98,867)(88,916)(113,396)
Nonoperating income11,3423315,3294,5354,1912,602
Investment income, nonoperating11,4001,0005,3004,500  
Interest and debt expense(44,353)(16,440)(15,963)(6,623)(3,797)(3,016)
Loss from continuing operations before equity method investments, income taxes:(357,213)(202,422)(104,577)(100,955)(88,522)(113,810)
Other undisclosed loss from continuing operations before income taxes     (17,767)(13,980)
Loss from continuing operations:(357,213)(202,422)(104,577)(100,955)(106,289)(127,790)
Loss before gain (loss) on sale of properties:(202,422)(104,577)(100,955)(106,289)(127,790)
Other undisclosed net loss(31,742)(12,892)(22,713)(20,737)  
Net loss:(388,955)(215,314)(127,290)(121,692)(106,289)(127,790)
Other undisclosed net loss attributable to parent      
Net loss available to common stockholders, diluted:(388,955)(215,314)(127,290)(121,692)(106,289)(127,790)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(388,955)(215,314)(127,290)(121,692)(106,289)(127,790)
Other comprehensive income (loss)(2,721)(1,018)(530)179157206
Other undisclosed comprehensive loss      
Comprehensive loss:(391,676)(216,332)(127,820)(121,513)(106,132)(127,584)
Other undisclosed comprehensive loss, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(391,676)(216,332)(127,820)(121,513)(106,132)(127,584)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: